Skip to main content

Displaying 1 - 20 of 4968

Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)

The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.

On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
221 0114
Docket Number
9437
Case Status
Pending
Report

An Atlas of US Physician Practice Choice and Firm Structure: 2015-2020, for Selected States from the FTC Physician and Facility Merger Study

Date
In this paper, we describe US physician practices using data from the Federal Trade Commission (FTC)’s Physician Practice and Healthcare Facility Merger Study. The data consists of healthcare claims...

The Boeing Co. /Spirit AeroSystems Holdings

The Federal Trade Commission will require The Boeing Company (Boeing) to divest significant Spirit AeroSystems Holdings, Inc. (Spirit) assets to resolve antitrust concerns surrounding Boeing’s $8.3 billion acquisition of Spirit.

On February 17, 2026, the FTC finalized the consent order in this matter.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
241 0098
Docket Number
C-4826
Case Status
Pending